Guided Biopsy for Mapping Prostate Cancer

Inclusion criteria

* Patients must have histologically confirmed diagnosis of prostate cancer * Patients must have elected to undergo radical prostatectomy using an open, laparoscopic or robotic approach * Patients must be at least 18 years of age and able to provide written informed consent. * No history of radiotherapy, chemotherapy or hormone therapy within 6 months of surgery * Primary tumor must be amenable to surgical removal for curative intent * Patients must have ECOG-performance status 0 or 1 (appendix II) * Patients must have no history of rectal or anal disease. * Patients must have adequate organ function as defined by the following criteria: * Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase \[SGOT\]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase \[SGPT\])≤2.5x local laboratory upper limit of normal (ULN), or AST and ALT ≤5x ULN if liver function abnormalities are due to underlying malignancy * Total serum bilirubin ≤1.5 x ULN * Absolute neutrophil count(ANC)≥1,500/microL * Platelets≥lOO,OOO/microL * Hemoglobin≥9.0 g/dL * Serum calcium≤10.2mg/dL (correct for low albumin if necessary; calcium + (normal albumin - serum albumin)x 0.8) * Patients must have serum creatinine\<2 mg/dL or serum creatinine clearance (CrCl)\>40ml/min(CrCl= Wt(kg)x(140-age)\*/72xCr. level,\*female x 0.85) Inclusion of minorities: * Members of all races and ethnic groups are eligible for this trial. Women and children are not eligible since prostate cancer is not diagnosed in these groups.